Achyut Dahal

The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections

Farhana Musarrat, Vladimir N. Chouljenko, Achyut Dahal et al. · Journal of Medical Virology · 2020 · 160 citations · Full text

Life Sciences, Infectious Diseases, Pathobiology +17

A pH-sensitive liposome formulation of a peptidomimetic-Dox conjugate for targeting HER2 + cancer

Jafrin Jobayer Sonju, Achyut Dahal, Sitanshu S. Singh et al. · International Journal of Pharmaceutics · 2021 · 39 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Synthesis, Characterization, and Evaluation of Near-IR Boron Dipyrromethene Bioconjugates for Labeling of Adenocarcinomas by Selectively Targeting the Epidermal Growth Factor Receptor

Nichole E. M. Kaufman, Qianli Meng, Kaitlin E. Griffin et al. · Journal of Medicinal Chemistry · 2019 · 37 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections

Farhana Musarrat, Vladimir N. Chouljenko, Rafiq Nabi et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 23 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16

A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models

Sitanshu S. Singh, George Mattheolabakis, Xin Gu et al. · European Journal of Medicinal Chemistry · 2021 · 20 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14